Mangoceuticals (MGRX) Income from Continuing Operations (2023 - 2026)

Mangoceuticals has disclosed Income from Continuing Operations across 4 years of filings, most recently posting 3403141.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 3403141.0, up 29.68% year-over-year; the trailing twelve-month figure through Mar 2026 was 19207107.0 (down 71.81% YoY), and the FY2025 annual result was 20643455.0, down 137.08% from the prior year.
• Income from Continuing Operations came in at 3403141.0 for Q1 2026 at Mangoceuticals, down from 2769370.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 1799460.0 in Q3 2023 to a low of 7618776.0 in Q3 2025.
• The 4-year median for Income from Continuing Operations is 2560885.0 (2023), against an average of 3228172.23.
• Across the five-year window, Income from Continuing Operations sank 281.0% in 2025 and grew 29.68% in 2026, its largest moves.
• Mangoceuticals' Income from Continuing Operations stood at 2568047.0 in 2023, then climbed by 24.12% to 1948596.0 in 2024, then tumbled by 42.12% to 2769370.0 in 2025, then slipped by 22.89% to 3403141.0 in 2026.
• The last three Income from Continuing Operations figures came in at 3403141.0 (Q1 2026), 2769370.0 (Q4 2025), and 7618776.0 (Q3 2025), per Business Quant data.